Export Revenue
₹961M
+232% YoY
Export revenue grew significantly, contributing 88% of total operating income.
ZIMLABORATORIES
Other
10 Feb 2026
Zim Laboratories Ltd — Q3 FY26
Zim Laboratories reported Q3 FY26 operating income of ₹1,087 crore, with EBITDA of ₹145 crore (13.4% margin) and PAT of ₹44 crore, showing sequential improvement.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Zim Laboratories reported Q3 FY26 operating income of ₹1,087 crore, with EBITDA of ₹145 crore (13.4% margin) and PAT of ₹44 crore, showing sequential improvement. Export revenue surged 232% YoY to ₹961 crore, contributing 88% of revenue. The EUGMP remediation remains the top priority; management expects the audit in Q1 FY27 (April-June 2026). NIP product commercialization in regulated markets is delayed until EUGMP clearance, but emerging market traction continues. A preferential issue of ₹35 crore was completed to fund capex and compliance. Key risk: further delay in EUGMP audit could push back regulated market entry and NIP revenue inflection.
Key Numbers
Inventory Days
94 days
flat
Inventory days remained stable at 94 days in Q3 FY26.
Receivable Days
105 days
flat
Receivable days stood at 105 days, consistent with prior periods.
R&D Spend
₹74M
flat
R&D expenditure of ₹74 million allocated for bio-studies and registrations.
Management Guidance
EU GMP audit expected in Q1 FY27
Management expects the EUGMP audit to occur in April-June 2026, with most CAPA responses submitted.
Management guidance otherNIP product revenue inflection post-EUGMP clearance
Once EUGMP is cleared, NIP product revenue could scale to ₹20 crore+ per quarter, with agreements already in place.
Management guidance revenue20% growth in emerging markets (ex-Bangladesh)
Management targets 20% growth in emerging markets excluding Bangladesh, driven by new hires and product registrations.
Management guidance growthDedicated block for key product to be operational by March 2027
A separate manufacturing block for a high-potential product will be converted into a site by March 2027, with MA expected within months.
Management guidance capexKey Risks
Delay in EUGMP audit
If the EUGMP audit is delayed beyond Q1 FY27, regulated market entry and NIP revenue inflection could be pushed out further.
high · management_commentaryPreferential issue pricing concerns
Analysts questioned the preferential issue at a low price, raising concerns about dilution and fair value.
medium · analyst_questionDependence on a single strategic investor
The company relied on one investor for the preferential issue, which may create concentration risk.
medium · analyst_questionMargin pressure from regulatory investments
Continued spending on CAPA and compliance initiatives may keep margins under pressure until regulated market revenue materializes.
medium · data_observationNotable Quotes
We are just waiting for the remediation related inspection and if everything is going well we will be well on the way to actually be able to demonstrate the promise that has shown to us.
Speed was of utmost importance here and price wise it is a mandated price on the base of last 90 days traded volume.
We are looking at about 20% growth in emerging markets ex-Bangladesh.
Frequently Asked Questions
What was Zim Laboratories's revenue in Q3 FY26?
Zim Laboratories reported revenue of ₹109 Cr in Q3 FY26, representing a — change compared to the same quarter last year.
What guidance did Zim Laboratories management give for FY27?
EU GMP audit expected in Q1 FY27: Management expects the EUGMP audit to occur in April-June 2026, with most CAPA responses submitted. NIP product revenue inflection post-EUGMP clearance: Once EUGMP is cleared, NIP product revenue could scale to ₹20 crore+ per quarter, with agreements already in place. 20% growth in emerging markets (ex-Bangladesh): Management targets 20% growth in emerging markets excluding Bangladesh, driven by new hires and product registrations. Dedicated block for key product to be operational by March 2027: A separate manufacturing block for a high-potential product will be converted into a site by March 2027, with MA expected within months.
What are the key risks for Zim Laboratories in FY27?
Key risks include Delay in EUGMP audit — If the EUGMP audit is delayed beyond Q1 FY27, regulated market entry and NIP revenue inflection could be pushed out further.; Preferential issue pricing concerns — Analysts questioned the preferential issue at a low price, raising concerns about dilution and fair value.; Dependence on a single strategic investor — The company relied on one investor for the preferential issue, which may create concentration risk.; Margin pressure from regulatory investments — Continued spending on CAPA and compliance initiatives may keep margins under pressure until regulated market revenue materializes..
Did Zim Laboratories meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Zim Laboratories Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.